NF1 Mutation clinical trials at UCSF

1 research study open to eligible people

The NF1 mutation alters genes that regulate cell growth. UCSF is evaluating the drug DCC-3084 in patients with tumors connected to the MAPK pathway. This Phase 1/2 trial explores the drug's effects when used alone or with other medications.

Showing trials for

  • DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

    open to eligible people ages 18 years and up

    This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

    San Francisco, California and other locations

Our lead scientists for NF1 Mutation research studies include .

Last updated: